Introduction
Hydroxylation of urate, catalyzed by urate oxidase (UOX), is the first and rate-limiting step of uricolysis, which changes uric acid to more soluble metabolic allantoin [1] . Lack of UOX in liver cells makes uric acid become the main end metabolic product of purine as well as the result of self-metabolism and food. The highest level of uric acid in women is 6 mg/dL and the highest level in men is 7 mg/dL [2, 3] . Recently, high concentration of uric acid in serum, also termed hyperuricaemia, becomes a common disease requiring stringent change in life-style and diet. It also becomes the "fourth high" following with hypertension, hyperlipidemia and hyperglycemia. Long term of high uric acid can lead to multiple organ involvement and tissue loss, such as arthritis, gout, kidney disease and cardiovascular disease. In addition, high uric acid content can also damage beta islet cells, reduce the sensitivity to insulin, resulting in the high incidence of diabetes mellitus type 2 [4] [5] [6] [7] [8] [9] . As of now, the treatment of hyperuricemia mainly focuses on drugs, such as probenecid, sulfinpyrazone, benzbromarone, allopurinol and xanthine oxidase inhibitor (XOI). Novel and more effective drugs are terribly needed to be investigated.
Zurampic, also termed Lesinurad, is usually recommended by physicians for the treatment of hyperuricemia combined with XOI [10] . Meanwhile, Zurampic is approved by US FDA for patients with gout because of the selective uric acid reabsorption inhibition [11] . Zurampic is reported to function through inhibition of urate transporter 1 (URAT1) which mainly responsible for reabsorption of uric acid from the glomerular ultrafiltrate into the epithelial cells of the renal proximal convoluted tubule [12, 13] . Therefore, we mainly focused on Zurampic to explore the potential therapeutic effects and possible underlying mechanisms.
Hyperuricaemia strongly correlates with insulin resistance and abnormal glucose metabolism [9] . Pancreatic β-cells participate in glucose metabolism and exert critical core roles. Oxidative stress injury has been reported to be involved in pancreatic β-cell injury induced by uric acid. It has been confirmed that uric acid can inhibit cell proliferation and increase oxidative stress, and subsequently inhibit insulin secretion by activating the reactive oxygen species (ROS)/adenosine monophosphate-activated protein kinase (AMPK)/ extracellular signal-regulated kinase (ERK) pathways [14] [15] [16] [17] [18] . Likewise, a previous study performed in pancreatic β cells has demonstrated uric acid triggers inhibition of oxidative stress and growth through activations of the AMPK and ERK signal pathways [17] . Thus, we also explored whether Zurampic could protect pancreatic β-cells against high uric acid induced-damage by modulation of the ROS/AMPK/ERK pathway.
In the present study, we attempted to evaluate the effects of Zurampic on high uric acid induced-damage in both rat pancreatic β-cell line INS-1 and primary rat islets, along with the possible underlying mechanisms.
Materials and Methods
Cell culture and treatment Rat INS-1 cells (Biohermes Ltd., Wuxi, China) were maintained in RPMI 1640 medium (Gibco-BR, Paisley, UK) supplemented with 10 mM glucose, 10% fetal bovine serum (FBS, Gibco), 1 mM sodium pyruvate, 10 mM HEPES, 2 mM glutamine, 50 μM β-mercaptoethanol, 100 U/mL penicillin, and 100 μg/mL streptomycin (all from Sigma, St. Louis, MO, USA). Primary rat islets were isolated as described previously with some modifications [19] . The procedure was approved by the ethical committee of the Affiliated Hospital of Qingdao University. In brief, Sprague-Dawley rats (male, weighing 250-300 g), purchased from Shanghai Laboratory Animal Center (Shanghai, China), were sacrificed with decapitation and the pancreas was isolated carefully. Then, a pancreas was digested by 5 mL collagenase XI (1000 U/mL; Sigma) in Hanks' balanced salt solution (HBSS) at 37°C for 16 min. After termination of digestion and islet separation by centrifugation, islets were handpicked under an inverted microscope. Primary rat islets were maintained in RPMI 1640 supplemented with 10 mM glucose, 10% fetal calf serum (Gibco-BR), 100 U/mL penicillin and 
Quantitative reverse transcription PCR (qRT-PCR) of URAT1
After incubation with various concentrations of Zurampic for 24 h, total RNA was isolated from INS-1 cells and primary rat islets by using TRIzol reagent, isopropanol and ethanol according to the manufacture's protocol (all from Sigma). Then, cDNA was synthesized after reverse transcription with Multiscribe RT kit (Applied Biosystems, Foster City, CA, USA) in line with supplier's instructions. Real-time PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems) following the instructions of manufacturer. Primers for URAT1 are: 5'-GAG GCA GAC ACG TTG ACT GT-3' (forward) and 5'-TTG CTT CCT AGG GCT TGC A-3' (reverse), and both were synthesized by Sangon (Shanghai, China). The URAT1 amplification conditions were as follows: pre-denaturation at 95°C for 5 min, 40 cycles of denaturation at 95°C for 15 s, annealing and extension at 61°C for 30 s, and then melting curve analysis at temperatures of 60-95°C, each sample was assessed 3 times [20] . Relative expression was calculated on the basis of the 2 -ΔΔCt method [21] , normalizing to GAPDH expression.
MTT assay for cell viability
Cell viability of INS-1 cells and primary rat islets treated with uric acid or uric acid plus Zurampic were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded with a density of 2 × 10 4 into 96-well plates and treated with 15 mg/dL uric acid or uric acid plus Zurampic. At 0, 24, 48, 72 and 96 h after treatment, culture medium was discarded and 100 μL MTT solution (0.5 mg/mL, Sigma) was added to each well, followed by incubation at 37°C for 4 h. Then, MTT solution was removed and 150 μL DMSO was added to dissolve the formazan crystals. The absorbance was measured at 492 nm on a microplate reader.
Cell apoptosis detection
Cell apoptosis was evaluated by an Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (BD Biosciences, San Diego, CA, USA). INS-1 cells and primary rat islets were plated in 6-well plates with a density of 1 × 10 6 cells per well and incubated under appropriate conditions (uric acid or uric acid plus Zurampic). The incubation after addition of uric acid was lasted for 24 h. To make single cell staining, cells were treated with trypsin-EDTA and centrifuged at 150 × g for 3 min at 4°C. After aspirating supernatants, cells were washed with 1 mL of Annexin V binding solution and centrifuged at 200 × g for 3 min at 4°C. Supernatants were removed and 3 μL of Annexin V-FITC and 10 μL of PI were added. After incubation for 15 min in the dark, 300 μL of binding buffer was added and the mixture was detected by an LSR II flow cytometry (BD Biosciences). The results were analyzed by FlowJo software (Tree Star, San Carlos, CA, USA).
ROS assessment by flow cytometry
INS-1 cells and primary rat islets were seeded into 6-well plates (2.5×10 5 cells/well) and maintained at 37°C for 24 h. Then, cells were exposed to uric acid (15 mg/dL) and uric acid plus Zurampic for 24 h, and stained with 10 μM 2, 7-dichlorodihydrofluorescein-diacetate (DCFA, Sigma) for 30 min at 37°C as previously described [17] . Stained cells were analyzed by an LSR fluorescent assisted cell sorting (FACS) machine (BD Biosciences) at emission wave-length 480 nm; excitation wave-length 530 nm. Data were given as percentage of cells in region "M". Each treatment condition contained three independent experiments.
Western blot analysis
After incubation with uric acid for 30 min, cells were scraped off with lysis buffer composed of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 µg/mL leupeptin, 1 mM phenylmethanesulfonyl fluoride (PMSF) and phosphatase inhibitors (phosphatase inhibitor mixture I). The supernatant protein concentration was determined by BCA Protein Assay Kit (Pierce, Rockford, IL, USA), and equivalent amount of proteins (80 Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry μg) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After that, proteins were transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA), followed by blocking with 5% non-fat milk and incubation with primary antibodies against phospho-ERK (p-ERK), ERK (both from Bioworld, St. Louis Park, MN, USA), phospho-AMPK (p-AMPK), AMPK, Caspase-3 and GAPDH (all from Cell Signaling Technology, Beverly, MA, USA). After rinsing, membranes were incubated with horseradish peroxidase-conjugated secondary antibody. Finally, an enhanced chemiluminescence kit (Pierce) was used for signal detection.
Enzyme-linked immunosorbent assay (ELISA) for glucose-stimulated insulin secretion
INS-1 cells and primary rat islets with a density of 2 × 10 5 cells/well were seeded into 24-well plates and cultured at 37°C for 48 h. Then, cells were washed with PBS and preincubated in 1 mL Krebs-Ringer bicarbonate HEPES buffer (KRBB: 115 mM NaCl, 24 mM NaHCO 3 , 5 mM KCl, 1 mM MgCl 2 , 25 mM HEPES, 0.5% BSA, pH 7.4) containing 2.8 mM glucose for 30 min with uric acid (15 mg/dL) or uric acid plus Zurampic. For glucose stimulation, the buffers were replaced by 1 mL KRBH with uric acid (15 mg/dL) or uric acid plus Zurampic containing 16.7 mM glucose. After an additional incubation for 60 min, the insulin concentration in supernatants of cell culture was determined by a rat insulin ELISA kit (Mercodia, Uppsala, Sweden) according to the protocol suggested by the supplier.
Statistical analysis
All the data were expressed as means ± SD of at least three independent experiments. Statistical analysis was performed using Graphpad Prism 5 software (GraphPad, San Diego, USA). The P-values were analyzed by two-tailed unpaired t test or two-way analysis of variance (ANOVA) with Bonferroni's correction. Differences of P < 0.05 were considered statistically significant.
Results

URAT1 expression is decreased by Zurampic stimulation in a dose-dependent manner
After being stimulated by different concentrations of Zurampic (0, 5, 10, 25 and 50 μg/mL), URAT1 expression was assessed by qRT-PCR. In Fig. 1A , the expression of URAT1 was significantly down-regulated by 5-50 μg/mL Zurampic (P < 0.05) in INS-1 cells. When compared to stimulation with 25 μg/mL Zurampic, the decrease of URAT1 expression was not statistically significant in the 50 μg/mL Zurampic group (P > 0.05). Meanwhile, in Fig. 1B , expression of URAT1 was markedly down-regulated by 10-50 μg/mL Zurampic (P < 0.05) in primary rat islets, whereas the decrease of URAT1 expression was not significant in the 5 μg/mL Zurampic as compared to the 0 μg/mL Zurampic group (P > 0.05). We concluded that URAT1 expression was decreased by Zurampic stimulation in a dose-dependent manner, and the concentration of Zurampic for further experiments was 25 μg/mL.
Suppressed cell viability by uric acid is abrogated by Zurampic
After treatments with uric acid or uric acid plus Zurampic for 96 h, cell viability was assessed by MTT assay. In Fig.2A-2B , cell viability of INS-1 cells and primary rat islets was significantly decreased by uric acid stimulation compared with non-treated cells at 24 h (both P < 0.05), 48 h (P < 0.01 or P < 0.001), 72 h (P < 0.01 or P < 0.001), and 96 h (both The Protective Role of Zurampic P < 0.001) post-stimulation. However, Zurampic stimulation markedly increased cell viability compared with cells treated by uric acid alone at 24 h (P < 0.05 or P < 0.01), 48 h (P < 0.01 or P < 0.001), 72 h (P < 0.01 or P < 0.001), and 96 h (both P < 0.001) poststimulation. The results suggested that uric acid reduced cell viability and the reduction could be reversed by Zurampic.
Enhanced cell apoptosis by uric acid is abrogated by Zurampic
After treatment with uric acid or uric acid plus Zurampic, cell apoptosis was assessed by flow cytometry. Results in Fig. 3A-3D showed that uric acid significantly increased cell apoptosis of INS-1 cells and primary rat islets as compared with nontreated cells (P < 0.01 or P < 0.001), whereas Zurampic abrogated the increases of cell apoptosis induced by uric acid when compared to cells treated with uric acid alone (both P < 0.01). Moreover, the Western blot analysis showed that the expression of cleaved Caspase-3 was obviously up-regulated by uric acid while the up-regulation was reversed by Zurampic in both INS-1 cells (Fig.  3E ) and primary rat islets (Fig. 3F) . Hence, we drew a conclusion that uric acid promoted cell apoptosis while the promotion could be abrogated by Zurampic.
ROS increase induced by uric acid is reduced by Zurampic
After treatments with uric acid or uric acid plus Zurampic, ROS level was assessed by FACS. In INS-1 cells (Fig. 4A-4B ) and primary rat islets (Fig. 4C-4D ), ROS level was significantly 
Activations of AMPK and ERK induced by uric acid are reversed by Zurampic
After treatments with uric acid, Zurampic and the inhibitors of AMPK (compound C) and ERK (PD98059), expression and phosphorylation of AMPK and ERK were assessed by Western blot analysis. In Fig.5A -5B, phosphorylation levels of AMPK and ERK were both significantly upregulated by uric acid (both P < 0.001) while these up-regulations were markedly abrogated by Zurampic (both P < 0.01) in both INS-1 and primary rat islets. Compared to the uric acid group, phosphorylation of AMPK and ERK was dramatically down-regulated by compound C (P < 0.01 or P < 0.001) and PD98059 (P < 0.01 or P < 0.001), respectively, in both INS-1 cells and primary rat islets. Moreover, the down-regulated AMPK and ERK, induced by Zurampic, were further reduced by compound C or PD98059 as compared to the uric acid + Zurampic group (all P < 0.001). Therefore, we concluded that Zurampic might function through inhibition of AMPK and ERK.
Decrease of insulin secretion induced by uric acid is rescued by Zurampic
After treatments with uric acid or uric acid plus Zurampic, along with 2.8 mM glucose or 16.7 mM glucose, the insulin secretion was evaluated by ELISA. ELISA results showed that insulin concentration of cells treated with 16.7 mM glucose was significantly higher than that treated with 2.8 mM glucose in both INS-1 cells (P < 0.01 or P < 0.001, Fig. 6A ) and primary rat islets (P < 0.05 or P < 0.001, Fig. 6B ). Under treatments with 16.7 mM glucose, insulin concentration was markedly reduced by uric acid compared with non-treated cells (P < 0.05), while the reduction was rescued by Zurampic compared with cells treated with uric acid (P < 0.05), in both INS-1 cells and primary rat islets. The results suggested that Zurampic had a protective effect on insulin secretion.
Discussion
Zurampic, an inhibitor of URAT1, is a US FDA approved drug which recommended for the treatment of gout when combined with XOI. However, survey revealed the influence 
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of Zurampic on pancreatic β-cells is yet to be established. In our study, we validated that Zurampic could down-regulate URAT1 mRNA expression in INS-1 cells and primary rat islets, and the most appreciate concentration was 25 μg/mL. The followed experiments demonstrated uric acid decreased cell viability and promoted cell apoptosis. In addition, uric acid significantly increased ROS level, along with activations of AMPK and ERK. Furthermore, 16.7 mM glucose-induced insulin secretion could be repressed by uric acid. Above all, we interestingly identified that all the effects of uric acid on INS-1 cells and primary rat islets could be abrogated by Zurampic. Accumulating literature has proposed that uric acid is involved in cell viability and apoptosis. A previous study once implied that uric acid decreased proximal tubular cell viability [22] . Another study gave the opposite evidence which proved suitable concentration of uric acid improved cell viability of HT22 hippocampal cells and BV-2 microglia [23] . Thus, A. INS-1 cells and primary rat islets were stimulated with vehicle, uric acid, uric acid plus Zurampic, uric acid plus compound C or uric acid plus Zurampic plus compound C, and phosphorylation levels of AMPK were assessed by Western blot analysis. B. INS-1 cells and primary rat islets were stimulated with vehicle, uric acid, uric acid plus Zurampic, uric acid plus PD98059 or uric acid plus Zurampic plus PD98059, and phosphorylation levels of ERK were assessed by Western blot analysis. The relative phosphorylation was expressed as the relative intensity of phosphorylated kinases/total kinases and the results were normalized by GAPDH. In addition, the final results of each group were also normalized to the data of the NC group. Data are presented as mean ± SD of three independent experiments. ** P<0.01; *** P<0.001. AMPK, adenosine monophosphate-activated protein kinase; ERK, extracellular signal-regulated kinase; p-, phospho-. 
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Cellular Physiology and Biochemistry the effects of uric acid on cell viability are varied depending on cell types. In our study, the cell viability of INS-1 cells and primary rat islets was significantly inhibited by uric acid. As for cell apoptosis, uric acid is reported to act as a promoter in human proximal tubule cells [22] . Meantime, hyperuricemia is proved to cause pancreatic β-cell death and dysfunction [24] . The results in our study were consistent with previous studies, indicating that uric acid obviously promoted cell apoptosis in INS-1 cells and primary rat islets. Considering the approved application of Zurampic in hyperuricemia, we explored the effects of Zurampic on uric acid-induced alterations of cell viability and apoptosis in INS-1 cells and primary rat islets. The results interestingly indicated Zurampic could reverse the effect of uric acid on cell viability and apoptosis. Uric acid has been reported to promote apoptosis by oxidative stress in human proximal tubule cells [22] . Yu et al. showed that uric acid inhibited cell proliferation, and induced senescence and apoptosis by local activation of oxidative stress and renin-angiotensin system in endothelial cells [25] . Therefore, we further explored the ROS level in INS-1 cells and primary rat islets treated with uric acid or uric acid plus Zurampic. In our study, the ROS level was markedly increased by uric acid which consisted with results reported previously. Moreover, Zurampic stimulation was proved to effectively abrogate the increase of ROS level induced by uric acid.
ERK is one of the downstream targets for oxidative stress. Accumulating studies showed that uric acid activated ERK phosphorylation in vascular smooth muscle cells and adipocytes [26, 27] . Simultaneously, AMPK is another target of oxidative stress. An array of reports demonstrated that AMPK was activated by oxidative stress in vascular endothelial and skin epidermal cells [28] [29] [30] . Observations in our study were consistent with these studies, showing that phosphorylation levels of AMPK and ERK were changed with the alterations of ROS level. Zhang et al. once reported uric acid induced oxidative stress and growth inhibition by activations of the AMPK and ERK signaling pathways [17] . In our study, the addition of the inhibitors of AMPK and ERK reinforced that Zurampic protected INS-1 cells and primary rat islets from uric acid-induced damage through inactivating AMPK and ERK.
Moreover, hyperuricaemia is strongly involved in insulin resistance and abnormal glucose metabolism [9] . In terms of pancreatic β-cells are the producers of insulin, thus the abnormal insulin secretion under glucose stimulation might be a common damage induced by uric acid. The results of our study were consistent with results by Rocic et al., showing that uric acid inhibited glucose-stimulated insulin secretion in pancreatic β-cells [31] . No surprisingly, Zurampic rescued the abnormal insulin secretion caused by uric acid in INS-1 cells and primary rat islets. Moreover, we found in our study there was no significant effect of uric acid on basal insulin release. However, the basal insulin release in the literature by Rocic et al. was inhibited by uric acid, which might contribute to the difference of glucose concentration in basal medium. The basal medium used in our study contained 2.8 mM glucose, whereas that in the previous literature contained 3.3 mM glucose. The slight difference of glucose concentration might be the reason for explaining the different results in our study and the previous study.
Taken together, we interestingly identified that Zurampic could protect INS-1 cells and primary rat islets against uric acid-induced damage on cell viability and apoptosis, ROS release, and insulin secretion through inhibiting URAT1 expression and inactivating the ROS/AMPK/ERK signaling pathways. The results might provide novel therapeutic strategies for high uric acid-induced diseases.
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